$VUZI
Vuzix Corp Stock $vuzi

$vuzi Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000114420417057779 Filed on November 09, 2017

Income Statement

Concept	2017 Q3	2016 Q3
Revenue	$1.405M	$583.00
YoY Change	240894.85%	-99.94%
Cost Of Revenue	$1.497M	$819.1K
YoY Change	82.77%	27.14%
Gross Profit	-$92.00K	-$237.00
YoY Change	38718.57%	-100.07%
Gross Profit Margin	-6.55%	-40.65%
Selling, General & Admin	$2.521M	$2.114M
YoY Change	19.26%	32.93%
% of Gross Profit
Research & Development	$1.506M	$2.178M
YoY Change	-30.84%	130.61%
% of Gross Profit
Depreciation & Amortization	$320.0K	$270.0K
YoY Change	18.52%	68.75%
% of Gross Profit
Operating Expenses	$5.430M	$4.292M
YoY Change	26.52%	69.33%
Operating Profit	-$5.522M	-$4.725M
YoY Change	16.88%	105.71%
Interest Expense	$12.59K	$33.98K
YoY Change	-62.94%	-17.03%
% of Operating Profit
Other Income/Expense, Net	$20.25K	-$310.8K
YoY Change	-106.52%	142.85%
Pretax Income	-$5.502M	-$5.036M
YoY Change	9.26%	107.67%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.502M	-$5.036K
YoY Change	109153.38%	-99.79%
Net Earnings / Revenue	-391.6%	-863.81%
Basic Earnings Per Share
Diluted Earnings Per Share	-$257.4K	-$292.7K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.700M	$5.900M
YoY Change	47.46%	-63.35%
Cash & Equivalents	$8.677M	$5.942M
Short-Term Investments
Other Short-Term Assets	$900.0K	$1.000M
YoY Change	-10.0%	-37.5%
Inventory	$2.800M	$4.000M
Prepaid Expenses
Receivables	$1.200M	$100.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$13.60M	$11.10M
YoY Change	22.52%	-44.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.900M	$3.070M
YoY Change	27.02%	283.81%
Goodwill
YoY Change
Intangibles		$540.1K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$4.900M	$3.868M
YoY Change	26.66%	93.42%
TOTAL ASSETS
Total Short-Term Assets	$13.60M	$11.10M
Total Long-Term Assets	$4.900M	$3.868M
Total Assets	$18.50M	$14.97M
YoY Change	23.59%	-32.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.800M	$1.530M
YoY Change	17.68%	282.39%
Accrued Expenses	$1.200M	$1.053M
YoY Change	13.93%	50.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$1.334M
YoY Change	-100.0%	1233.71%
Total Short-Term Liabilities	$3.300M	$4.354M
YoY Change	-24.21%	234.93%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$0.00	$300.0K
YoY Change	-100.0%	0.0%
Total Long-Term Liabilities	$0.00	$328.8K
YoY Change	-100.0%	-78.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.300M	$4.354M
Total Long-Term Liabilities	$0.00	$328.8K
Total Liabilities	$3.300M	$4.683M
YoY Change	-29.53%	73.44%
SHAREHOLDERS EQUITY
Retained Earnings		$76.84M
YoY Change
Common Stock		$17.48K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.20M	$10.29M
YoY Change
Total Liabilities & Shareholders Equity	$18.50M	$14.97M
YoY Change	23.59%	-32.27%

Cashflow Statement

Concept	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$5.502M	-$5.036K
YoY Change	109153.38%	-99.79%
Depreciation, Depletion And Amortization	$320.0K	$270.0K
YoY Change	18.52%	68.75%
Cash From Operating Activities	-$4.540M	-$3.650M
YoY Change	24.38%	1.96%
INVESTING ACTIVITIES
Capital Expenditures	-$820.0K	-$760.0K
YoY Change	7.89%	80.95%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$820.0K	-$760.0K
YoY Change	7.89%	-116.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$7.978M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.920M	5.770M
YoY Change	37.26%	19133.33%
NET CHANGE
Cash From Operating Activities	-4.540M	-3.650M
Cash From Investing Activities	-820.0K	-760.0K
Cash From Financing Activities	7.920M	5.770M
Net Change In Cash	2.560M	1.360M
YoY Change	88.24%	32.04%
FREE CASH FLOW
Cash From Operating Activities	-$4.540M	-$3.650M
Capital Expenditures	-$820.0K	-$760.0K
Free Cash Flow	-$3.720M	-$2.890M
YoY Change	28.72%	-8.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	vuzi	Accrued Revenuecurrent AccruedRevenuecurrent	0	USD
CY2017Q3	vuzi	Accrued Revenuecurrent AccruedRevenuecurrent	687001	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1367766	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3002744	USD
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	139500	USD
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	938281	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1507266	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	3941025	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2069964	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3441650	USD
	us-gaap	Cost Of Services CostOfServices	39060	USD
	us-gaap	Cost Of Services CostOfServices	872137	USD
	us-gaap	Cost Of Revenue CostOfRevenue	2109024	USD
	us-gaap	Cost Of Revenue CostOfRevenue	4313787	USD
	us-gaap	Gross Profit GrossProfit	-601758	USD
	us-gaap	Gross Profit GrossProfit	-372762	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5121713	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4374202	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2627543	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2739978	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3350441	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4155960	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	549244	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	734175	USD
	us-gaap	Taxes Other TaxesOther	53749	USD
	us-gaap	Taxes Other TaxesOther	37884	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-21267	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-30299	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-664392	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-225479	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12915091	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13754038	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12915091	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1203693	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1273029	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	34867	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	19500	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.86
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13528559	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12250699	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	155760	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	391334	USD
CY2017Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1138413	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	582549	USD
CY2017Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	266687	USD
CY2016Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	0	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1405100	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	582549	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	819116	USD
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1089881	USD
CY2016Q3	us-gaap	Cost Of Services CostOfServices	0	USD
CY2017Q3	us-gaap	Cost Of Services CostOfServices	407220	USD
CY2017Q3	us-gaap	Cost Of Revenue CostOfRevenue	1497101	USD
CY2016Q3	us-gaap	Cost Of Revenue CostOfRevenue	819116	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	-236567	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	-92001	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2177957	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1274698	USD
CY2016Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	196370	USD
CY2017Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	251366	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4725089	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5522495	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	12956	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	8144	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	45800	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	20923	USD
CY2017Q3	us-gaap	Taxes Other TaxesOther	15734	USD
CY2016Q3	us-gaap	Taxes Other TaxesOther	19124	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5246	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-13781	USD
CY2017Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	41454	USD
CY2016Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-59120	USD
CY2016Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	11707	USD
CY2017Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Interest Expense InterestExpense	77849	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	12592	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	33981	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-310772	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5502242	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5035861	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5502242	USD
CY2017Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	435321	USD
CY2016Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	410153	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5937563	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5446014	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15027067	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14118784	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17216374	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20515363	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16489522	shares
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	77537	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-142347	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12091984	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10038160	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1197452	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1551141	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	155284	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	103375	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1681940	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1654516	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	52416	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7917321	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5757279	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5856603	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5935397	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11877058	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5941661	USD
	us-gaap	Interest Paid Net InterestPaidNet	310	USD
	us-gaap	Interest Paid Net InterestPaidNet	7860	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	241300	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	100000	USD
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	214836	USD
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	214838	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	300796	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-392242	USD
	vuzi	Increase Decrease In Vendors Prepayments IncreaseDecreaseInVendorsPrepayments	-163471	USD
	vuzi	Increase Decrease In Vendors Prepayments IncreaseDecreaseInVendorsPrepayments	-26644	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	342034	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1861283	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	0	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-240110	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	50598	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-57133	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	19500	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	34867	USD
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	329204	USD
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	45000	USD
	vuzi	Increasedecrease In Accrued Revenue IncreasedecreaseInAccruedRevenue	687001	USD
	vuzi	Increasedecrease In Accrued Revenue IncreasedecreaseInAccruedRevenue	0	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	19250082	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	13427478	USD
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	19238015	USD
	us-gaap	Earnings Per Share Potentially Dilutive Securities EarningsPerSharePotentiallyDilutiveSecurities	6,532,259
CY2016	us-gaap	Earnings Per Share Potentially Dilutive Securities EarningsPerSharePotentiallyDilutiveSecurities	7,227,738
CY2017Q3	us-gaap	Inventory Raw Materials And Purchased Parts Net Of Reserves InventoryRawMaterialsAndPurchasedPartsNetOfReserves	2069378	USD
CY2016Q4	us-gaap	Inventory Raw Materials And Purchased Parts Net Of Reserves InventoryRawMaterialsAndPurchasedPartsNetOfReserves	1990026	USD
CY2017Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	212444	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	454120	USD
CY2017Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1217700	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	831069	USD
CY2017Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	656931	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	623997	USD
CY2017Q3	us-gaap	Interest Payable Current InterestPayableCurrent	183553	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	141645	USD
CY2017Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	114056	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	102260	USD
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	175184	USD
	vuzi	Percentage Of Outstanding Warrants Issued By Parent PercentageOfOutstandingWarrantsIssuedByParent	0.86	pure
CY2017Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	38100	shares
CY2017Q3	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	122533	USD
CY2017Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	122533	USD
CY2016Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	173131	USD
CY2016Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	173131	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-50598	USD
CY2017Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	122533	USD
CY2017Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	49626	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	49626	shares
CY2017Q3	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	4407158	USD
CY2016Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	3134129	USD
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22178911	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	401859	shares
	vuzi	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	250009	shares
	vuzi	Class Of Warrant Or Right Grants In Period ClassOfWarrantOrRightGrantsInPeriod	0	shares
CY2017Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	151850	shares
	vuzi	Class Of Warrant Or Right Expired In Period ClassOfWarrantOrRightExpiredInPeriod	0	shares
	vuzi	Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Terms ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerms	P8M12D
	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	2.66
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	716046	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.63
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	701763	shares
	vuzi	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	5.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P8Y8M12D
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3512000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	192000	USD
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2020-10-03
	vuzi	Operating Lease Commencement Date OperatingLeaseCommencementDate	2015-10-03
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1091254	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	93053	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	348900	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	341990	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	307311	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	344227	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	371239	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1861283	USD
	vuzi	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	0	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	912102	USD
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	49626	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22178911	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	100000	USD
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19569247	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19569247	shares
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	173131	USD
CY2016Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	41132	USD
CY2017Q3	us-gaap	Long Term Debt LongTermDebt	0	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	1416480	USD
CY2017Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1490000	shares
CY2017Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.75
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7978321	USD
CY2017Q3	us-gaap	Inventory Write Down InventoryWriteDown	1151482	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	335000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8628500	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	650179	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2016Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	1151482	USD
CY2017Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-585	USD
CY2016Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-25890	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-585	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-25890	USD
	vuzi	Common Stock Awards Compensation Expense CommonStockAwardsCompensationExpense	83750	USD
	vuzi	Common Stock Awards Compensation Expense CommonStockAwardsCompensationExpense	174025	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8567500	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6612500	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	650179	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	847805	USD
CY2017Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	122533	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	38100	shares
CY2017Q3	vuzi	Subscription Receivable From Officer SubscriptionReceivableFromOfficer	61000	USD
CY2016Q4	vuzi	Subscription Receivable From Officer SubscriptionReceivableFromOfficer	0	USD
	us-gaap	Increase Decrease In Due From Officers And Stockholders Current IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent	0	USD
	us-gaap	Increase Decrease In Due From Officers And Stockholders Current IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent	61000	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 34.55pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Note 1  Basis of Presentation</font></font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 34.55pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The accompanying unaudited Condensed Consolidated Financial Statements of Vuzix Corporation and Subsidiaries (“the Company") have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission. Accordingly, the unaudited Condensed Consolidated Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December 31, 2016 was derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (the “Annual Report”).</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements of the Company as of December 31, 2016, as reported in the Company’s Annual Report.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">For the nine months ended September 30, 2017, Toshiba Japan represented substantially all of engineering revenues and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 24</font>% of total revenues as compared to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>% in the same 2016 period. As of September 30, 2017 and 2016, Toshiba Japan accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 59</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>% of accounts receivables and accrued project revenue, respectively.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The accompanying Condensed Consolidated Financial Statements have been prepared assuming that we will continue as a going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These Condensed Consolidated Financial Statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should we be unable to continue as a going concern. The Company incurred a net loss for the nine months ended September 30, 2017 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,754,038</font>. The Company has incurred a net loss consistently over recent years. The Company incurred annual net losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,250,082</font> in 2016 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,427,478</font> in 2015, and has an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,592,988</font> as of September 30, 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company’s cash requirements are primarily for funding operating losses, research, capital expenditures and working capital. Historically, the Company has met these cash needs by borrowings under notes, sales of convertible debt, and the sales of equity. In 2016, we received total net proceeds from public equity offerings of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,238,015</font>, after underwriting discounts and commissions and other offering expenses. On August 14, 2017 the Company closed on the sale of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,490,000</font> shares of its common stock to investors in a public offering at an offering price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.75</font> per share. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">As part of the same offering, we sold an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000</font> shares of common stock to an executive officer at the closing market price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.10</font> per share, to comply with certain Nasdaq rules. As of September 30, 2017, there was a subscription receivable </font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">61,000</font> related to the above offering due from that executive officer. The total balance of that subscription receivable was paid in-full on October 3, 2017. The Company’s net proceeds after commissions and expenses wer</font>e $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,978,321</font>.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Our cash requirements related to funding operating losses depend upon numerous factors, including new product development activities, our ability to commercialize our products, our products’ timely market acceptance, selling prices and gross margins, and other factors. In order for us to achieve positive cash flow from operations, our product sales will need to significantly increase</font>.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">   </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company’s management intends to take actions necessary to continue as a going concern, as discussed herein. The Company will need to grow its business significantly to become profitable and self-sustaining on a cash flow basis. Management’s plans concerning these matters and managing our liquidity include among other things:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">the commencement of full and higher volume manufacturing of the new M300 Smart Glasses with assembly offshore in the summer of 2017, on a turnkey basis, which should result in further product margin improvements and supply chain investments, as demonstrated in our third quarter;</font></font></div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">   </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;CLEAR: both"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">the award of a Smart Glasses development program with Toshiba, which we expect to be completed by end of 2017 and represents approximately a further $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">221,000</font> in revenues, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">which thereafter should move into volume production in early 2018 with a proposed supply and purchase agreement that we expect will result in a minimum of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000,000</font> in new revenues for the Company in the 12 month period following the commencement of volume deliveries;</font></font></div> </div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">tighter control of operating costs and reduction in spending growth rates wherever possible;</font></font></div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">slowing of planned new product development based on new technologies as well as reduced discretionary and non-essential capital expenditures not related to select near-term new products</font>;</font></div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">reducing the rate of research and development spending on new technologies, particularly the use of costly external contractors, for our upcoming smart glasses models that will first be manufactured at our Rochester plant rather than at external contractors, where we incur high start-up costs and the requirement for bigger production commitments that consume working capital;</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font> </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"><font style="FONT-FAMILY:Symbol"> ⋅</font></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY:times new roman,times,serif"> better leveraging our product and technology base and creating new product models that are derivatives (rather than completely new) and which therefore are less costly to develop and introduce to the marketplace; and</font></font> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> ⋅</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">attempting to utilize conventional bank operating loan financing to help grow our working capital base to support our investments in accounts receivable and inventory as sales revenues grow.</font></div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">   </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">However, if these actions are not successful in the near term, we will have to raise additional capital to maintain operations and/or materially reduce our operating and new product development costs.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">If the Company raises additional funds by selling equity, the ownership interest of existing stockholders may be diluted. The amount of such dilution could increase further due to the issuance of securities with new warrants or convertibility features with other dilutive characteristics, such as anti-dilution clauses or price resets</font>.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Based upon our current amount of cash on hand, management’s historical ability to raise capital, and our ability to manage our cost structure and adjust operating plans if and as required, we have concluded that substantial doubt of our ability to continue as a going concern has been alleviated.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q3	vuzi	Subscription Receivable From Officer SubscriptionReceivableFromOfficer	61000	USD
CY2017Q3	us-gaap	Significant Supply Commitment Remaining Minimum Amount Committed SignificantSupplyCommitmentRemainingMinimumAmountCommitted	5000000	USD

Files In Submission

Name	View Source	Status
0001144204-17-057779-index-headers.html	Edgar Link	pending
0001144204-17-057779-index.html	Edgar Link	pending
0001144204-17-057779.txt	Edgar Link	pending
0001144204-17-057779-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv478527_10q.htm	Edgar Link	pending
tv478527_ex31-1.htm	Edgar Link	pending
tv478527_ex31-2.htm	Edgar Link	pending
tv478527_ex32-1.htm	Edgar Link	pending
tv478527_ex32-2.htm	Edgar Link	pending
vuzi-20170930.xml	Edgar Link	completed
vuzi-20170930.xsd	Edgar Link	pending
vuzi-20170930_cal.xml	Edgar Link	unprocessable
vuzi-20170930_def.xml	Edgar Link	unprocessable
vuzi-20170930_lab.xml	Edgar Link	unprocessable
vuzi-20170930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VUZI
Vuzix Corp Stock $vuzi

2017 Q3 Form 10-Q Financial Statement

#000114420417057779 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VUZI Vuzix Corp Stock $vuzi

2017 Q3 Form 10-Q Financial Statement

#000114420417057779 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VUZI
Vuzix Corp Stock $vuzi